TIGER
A randomised phase III trial comparing conventional dose chemotherapy using Paclitaxel, Ifosfamide and Cisplatin (TIP) with high dose chemotherapy using mobilising Paclitaxel plus Ifosfamide followed by high dose Carboplatin and Etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours.
Disease site: Testicular cancer, urological cancers
Treatment modality: Systematic therapy
Status: In Follow-up
Trial details
TIGER is a phase III, international multicentre, randomised controlled trial comparing the use of conventional chemotherapy with high-dose chemotherapy as first salvage treatment in patients with relapsed or refractory germ cell tumours.
45 patients have been recruited from UK sites, with a total of 420 patients recruited worldwide over seven years. TIGER closed recruitment on 26th October 2022. Patients were randomised to one of two treatment groups:
- conventional chemotherapy using the TIP regimen (Paclitaxel, Ifosfamide and Cisplatin)
- or high-dose chemotherapy with autologous stem cell transplant using the TI-CE regimen (Paclitaxel and Ifosfamide followed by high-dose Carboplatin and Etoposide).
Patients will be followed up for five years from randomisation.
Further information
UK Chief Investigator: Professor Robert Huddart, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
European Lead: Professor Thomas Powles, Barts Health NHS Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: [email protected]
ISRCTN: To be confirmed
European Sponsor: EORTC
U.S. Sponsor: Alliance
Funding: Cancer Research UK (CRUK/12/049)
View TIGER on the National Institute for Health Research website:
NIHR - Be Part Of Research
Patient friendly information is available from the following link:
Cancer Research UK
Publications and presentations
There have been no presentations or publications to date.